Alnylam Pharmaceuticals this week said that the US Patent and Trademark Office has issued a notice of allowance for one of the company's patent applications related to lipid nanoparticles for systemic RNAi drug delivery.
Alnylam said that the patent application, No. 20100324120, is entitled “Lipid Formulation.” Alnylam said that it covers a variety of second-generation lipid nanoparticles including the so-called MC3 lipids used in the company's transthyretin-mediated amyloidosis drug ALN-TTR02 and its hypercholesterolemia treatment ALN-PCS.
Notably, ownership of the MC3 class of lipids is being disputed in an ongoing lawsuit between Alnylam and partner Tekmira Pharmaceuticals (GSN 3/17/2011).
Tekmira's management has stated publicly that Alnylam “stole” the MC3 technology.